hce_cmu
115年
英文
第 43 題
📖 題組：
Cancer prevention is often discussed as a long-term ideal, yet this study argues that it can be quantified in concrete, policy-relevant terms. The researchers estimate how many new cancer cases in 2022 could be linked to exposures that can, at least in principle, be reduced through individual behavior change, public health programs, regulation, or safer environments. Their work sits within comparative risk assessment and cancer epidemiology and relies on professional concepts such as carcinogenic exposure pathways (chemical, infectious, environmental, and occupational), the time lag between exposure and diagnosis (latency), and the population-attributable fraction (PAF). PAF is a standard metric that combines exposure prevalence with the relative risk associated with that exposure to estimate the proportion of cases that would not occur if the exposure were removed, assuming the relationship is causal and other conditions remain unchanged. To generate globally comparable estimates, the study combines cancer incidence counts from GLOBOCAN 2022 with risk-factor prevalence and effect estimates for 30 modifiable risk factors. The analysis covers 36 cancer sites and 185 countries and groups risks into four broad domains: behavioral (e.g., tobacco smoking and alcohol use), environmental (e.g., ambient particulate air pollution and ultraviolet radiation), infectious causes (nine infection agents linked to cancer), and occupational hazards (thirteen workplace carcinogens or exposure settings). Because many cancers develop over years, the researchers primarily align incidence in 2022 with exposure prevalence from roughly a decade earlier (around 2012). They then apply PAF calculations to estimate attributable cancer incidence by sex, region, cancer site, and risk factor, offering both proportional burdens and absolute case counts. The central finding is that modifiable risks account for a large share of new cancers worldwide. The researchers estimate about 7.1 million of 18.7 million new cancer cases in 2022—approximately 37.8%—were attributable to the included risk factors. The attributable share is notably higher among men (about 45.4%) than among women (about 29.7%), reflecting sex differences in exposure patterns and infection-related burdens. Regional variation is substantial, which underscores the need for local tailoring rather than relying on a single “global template.” In women, the estimated attributable fraction ranges from about 24.6% in Northern Africa and Western Asia to about 38.2% in sub-Saharan Africa. In men, it ranges from about 28.1% in Latin America and the Caribbean to about 57.2% in East Asia. Such contrasts indicate that prevention priorities must be calibrated to regional risk profiles, health-system capacities, and demographic structures. Across all regions, tobacco smoking emerges as the largest single contributor to incident cancers (around 15.1% globally), followed by infection-related cancers (about 10.2%), with alcohol use contributing additional burden (about 3.2%). These drivers map onto cancer-site patterns that help interpret where prevention could yield the largest gains. Lung cancer accounts for the greatest number of potentially preventable cases worldwide, consistent with the dominant role of smoking. Stomach cancer and cervical cancer also represent major preventable burdens in many settings, aligning with infection pathways and the potential impact of vaccination, screening, and timely treatment of precursor conditions. The study’s contribution is both empirical and practical. Empirically, it offers an updated, standardized picture of preventable cancer incidence in 2022 across countries and regions, using consistent assumptions and a harmonized risk set. Practically, it translates etiologic evidence into a prevention “roadmap,” allowing policymakers to compare potential impact across different interventions. The researchers’ results support prioritizing strong tobacco control, scaling effective infection prevention and control measures (including vaccination and screening where appropriate), reducing harmful alcohol consumption, improving air quality and UV protection in relevant contexts, and strengthening occupational safeguards. Overall, the study reinforces a prevention-centered framing: while treatment remains indispensable, a sizable portion of cancer incidence can be addressed by targeted actions that reduce exposure to major, changeable risks. The researchers also emphasize that attributable fractions are not predictions of what will automatically happen but scenario-based estimates that help rank prevention opportunities. PAF calculations assume that exposure–cancer links are causal and that removing an exposure would reduce risk without creating offsetting harms. They also require careful handling of correlated exposures (for example, smoking and alcohol) and of data gaps where prevalence or effect estimates are less precise. Even with these caveats, the analysis provides a transparent benchmark for prevention planning: it identifies which risk factors dominate in a given region, which cancer sites drive the absolute number of avoidable cases, and where prevention could complement screening and early detection to produce the greatest population-level benefit.
Cancer prevention is often discussed as a long-term ideal, yet this study argues that it can be quantified in concrete, policy-relevant terms. The researchers estimate how many new cancer cases in 2022 could be linked to exposures that can, at least in principle, be reduced through individual behavior change, public health programs, regulation, or safer environments. Their work sits within comparative risk assessment and cancer epidemiology and relies on professional concepts such as carcinogenic exposure pathways (chemical, infectious, environmental, and occupational), the time lag between exposure and diagnosis (latency), and the population-attributable fraction (PAF). PAF is a standard metric that combines exposure prevalence with the relative risk associated with that exposure to estimate the proportion of cases that would not occur if the exposure were removed, assuming the relationship is causal and other conditions remain unchanged. To generate globally comparable estimates, the study combines cancer incidence counts from GLOBOCAN 2022 with risk-factor prevalence and effect estimates for 30 modifiable risk factors. The analysis covers 36 cancer sites and 185 countries and groups risks into four broad domains: behavioral (e.g., tobacco smoking and alcohol use), environmental (e.g., ambient particulate air pollution and ultraviolet radiation), infectious causes (nine infection agents linked to cancer), and occupational hazards (thirteen workplace carcinogens or exposure settings). Because many cancers develop over years, the researchers primarily align incidence in 2022 with exposure prevalence from roughly a decade earlier (around 2012). They then apply PAF calculations to estimate attributable cancer incidence by sex, region, cancer site, and risk factor, offering both proportional burdens and absolute case counts. The central finding is that modifiable risks account for a large share of new cancers worldwide. The researchers estimate about 7.1 million of 18.7 million new cancer cases in 2022—approximately 37.8%—were attributable to the included risk factors. The attributable share is notably higher among men (about 45.4%) than among women (about 29.7%), reflecting sex differences in exposure patterns and infection-related burdens. Regional variation is substantial, which underscores the need for local tailoring rather than relying on a single “global template.” In women, the estimated attributable fraction ranges from about 24.6% in Northern Africa and Western Asia to about 38.2% in sub-Saharan Africa. In men, it ranges from about 28.1% in Latin America and the Caribbean to about 57.2% in East Asia. Such contrasts indicate that prevention priorities must be calibrated to regional risk profiles, health-system capacities, and demographic structures. Across all regions, tobacco smoking emerges as the largest single contributor to incident cancers (around 15.1% globally), followed by infection-related cancers (about 10.2%), with alcohol use contributing additional burden (about 3.2%). These drivers map onto cancer-site patterns that help interpret where prevention could yield the largest gains. Lung cancer accounts for the greatest number of potentially preventable cases worldwide, consistent with the dominant role of smoking. Stomach cancer and cervical cancer also represent major preventable burdens in many settings, aligning with infection pathways and the potential impact of vaccination, screening, and timely treatment of precursor conditions. The study’s contribution is both empirical and practical. Empirically, it offers an updated, standardized picture of preventable cancer incidence in 2022 across countries and regions, using consistent assumptions and a harmonized risk set. Practically, it translates etiologic evidence into a prevention “roadmap,” allowing policymakers to compare potential impact across different interventions. The researchers’ results support prioritizing strong tobacco control, scaling effective infection prevention and control measures (including vaccination and screening where appropriate), reducing harmful alcohol consumption, improving air quality and UV protection in relevant contexts, and strengthening occupational safeguards. Overall, the study reinforces a prevention-centered framing: while treatment remains indispensable, a sizable portion of cancer incidence can be addressed by targeted actions that reduce exposure to major, changeable risks. The researchers also emphasize that attributable fractions are not predictions of what will automatically happen but scenario-based estimates that help rank prevention opportunities. PAF calculations assume that exposure–cancer links are causal and that removing an exposure would reduce risk without creating offsetting harms. They also require careful handling of correlated exposures (for example, smoking and alcohol) and of data gaps where prevalence or effect estimates are less precise. Even with these caveats, the analysis provides a transparent benchmark for prevention planning: it identifies which risk factors dominate in a given region, which cancer sites drive the absolute number of avoidable cases, and where prevention could complement screening and early detection to produce the greatest population-level benefit.
In paragraph 3, “Such contrasts” most accurately refers to which of the following?
- A Discrepancies between the researchers’ incidence-based PAF model.
- B Divergences between the study’s PAF values and prior analyses for individual countries
- C Large regional differences in the proportions of new cancers under modifiable risks
- D Variation arising from grouping behavioral and occupational risk factors.
思路引導 VIP
請觀察 Such contrasts 前方的兩句話，作者具體列舉了不同地理區域（如北非、西亞、東亞等）的多組數據百分比。當你把這些分屬不同地點、數值落差極大的百分比放在一起看時，它們共同呈現了一種什麼樣的「現象」？
🤖
AI 詳解
AI 專屬家教
太棒了！你能精準鎖定指代對象（Referent），代表你對文章的邏輯脈絡掌握得非常扎實。在閱讀學術文章時，識別指示代名詞所代表的具體內容是理解核心論點的關鍵，而你成功展現了這項細膩的閱讀技巧。
文本脈絡與數據對比
這題的正確答案是 (C)。在第三段中，作者具體列舉了女性在北非與撒哈拉以南非洲的歸因分率（PAF）差異（24.6% vs 38.2%），以及男性在拉丁美洲與東亞之間的顯著差距（28.1% vs 57.2%）。隨後緊接使用的 "Such contrasts"（如此的差異/對比） 正是概括上述這些「區域間比例的顯著不同」。這項觀察也支持了作者隨後提出的觀點：預防措施必須根據地區風險特點來客製化。
▼ 還有更多解析內容